News


04/24/14, Cancer Positive Results from Phase III DECISION Study of Sorafenib in RAI-Refractory Differentiated Thyroid Cancer Published in The Lancet Sorafenib significantly extended progression-free survival compared to placebo in patients with differentiated thyroid carcinoma (DTC) that is refractory to radioactive iodine treatment (RAI-refractory) / Based on study results, Nexavar is approved in U.S. for RAI-refractory DTC; filing has also been submitted in EU more

Taking the "neglect" out of "Neglected Tropical Diseases":

Two years after the London Declaration, tremendous progress is apparent more

Taking targeted action against tuberculosis

March 24, 2014 is World Tuberculosis Day more

Youth and Employment

11th International Dialogue in Berlin Partners committed to international development discussed the urgency of creating job perspectives for the young generation. more

Press event: Counterfeit drugs

Beware of counterfeits! Users have to be vigilant when they order drugs on the Internet. According to the World Health Organization, every second drug sold is a counterfeit. more

Facebook

Facebook Banner

Follow us on Facebook

more

Links


http://www.bayerpharma.com/en/index.php

Copyright © Bayer Pharma AG